Senseonics (SENS) reported a robust first quarter for 2026, achieving $11.7 million in revenue—an impressive 85% increase year-over-year—driven by strong adoption of its Eversense 365 continuous glucose monitoring system. The company’s gross margin also expanded to 58%, bolstered by higher manufacturing volumes and the elimination of revenue-sharing agreements. Notably, the direct-to-consumer (DTC) channel has become a significant growth driver, accounting for 60% of new patient shipments and doubling year-over-year.
The strong financial performance and successful integration of the U.S. commercial organization position Senseonics favorably for future growth. The company has raised its full-year revenue guidance to between $60 million and $64 million, reflecting a targeted growth rate of 70% to 82%. Additionally, the launch of Eversense in European markets and the establishment of Eon Care for easier patient access further enhance its competitive edge.
Market professionals should note that the company’s strategic focus on expanding its DTC channel and improving patient retention could lead to sustained revenue growth and profitability, despite rising operating expenses.
Source: fool.com